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1. Introduction 
Regenerative medicine can be defined as the process of restoring diseased or damaged 
tissue by replacing it with biological substitutes and this issue represents one of the main 
concerns of medicine. Stem cells are likely to be used in the future for cardiac, neurologic, 
hepatic, orthopaedic and other applications. The stem cell populations have proved to be 
highly proliferative lately as isolated from a variety of embryonic, foetal and adult tissues. 
Their increased capacity to self-renew and to unlimitedly differentiate into derivates of all 
germ layers in vitro and in vivo have rendered embryonic stem cells (ESCs) the main 
concern of tissue engineering research and regenerative medicine (Hyslop et al., 2005). 
However these cell lines originate from the inner cell mass of human blastocysts. Thus, the 
relation of ESCs to the human blastocyst will always stir ethical, moral and emotional 
debate over their use in research. Moreover, besides these ethical and political issues, 
another drawback concerning their clinical application is their lack of accessibility, 
technique difficulties in purification and manipulation as well as the risk for teratoma 
development (Fan et al., 2011). Consequently, though ESC therapy has just come into 
attention and there still are unknowns, its success might result in it being followed by 
alternative stem cell therapies (Rogers & Casper, 2004).  
Adult stem cells (ASCs) originate in a mature organism, including the brain, fat, skin, 
kidney, peripheral blood and bone marrow and they contribute to maintaining and 
repairing tissue that contain them. The adult-derived stem cells are also believed to have the 
ability to differentiate into tissues different from their tissue of origin (Krause et al., 2001; 
Jiang et al, 2002). Different from ESCs, ASCs can be easily harvested from various tissues, 
such as skin (Riekstina et al., 2008 as cited in Fan et al., 2011), bone marrow (BM) (Gastens et 
al., 2007 as cited in Fan et al., 2011) and adipose (Keiser et al., 2007 as cited in Fan et al., 
2011), and might be employed in the clinical treatment of disorders of vulnerable vital 
organs. ASCs have the advantage that allows for small samples of tissues or even the 
patient’s own cells to be used for implantation, avoiding problems of tissue rejection. 
Moreover, adult cells do not involve the typical ethical issues of embryonic research. In spite 
of these advantages, they are not the first choice and this is because of several reasons such 
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as their limited numbers, diminished growth and differential capacities age-dependent as 
well as invasive harvesting procedures (Roobrouck et al., 2008). 
Compared to the extensive research on ESCs and ASCs, fetal stem cells have only recently 
come into attention (Fan et al., 2011). The transplant of fetal tissue has recently become a 
research therapy for chronic degenerative disease such as Parkinson’s disease and insulin-
dependent diabetes mellitus (DM). However, this method is widely opposed as fetal tissue 
originates from elective abortion (Rogers & Casper, 2004). However, the following two 
distinct sources have lately generated putative stem cells: the fetus proper (including fetal 
bone marrow (Chang et al., 2006 as cited in Fan et al., 2011), lung (Fan et al., 2005 as cited in 
Fan et al, 2011), spleen, liver (In’t Anker et al., 2003 as cited in Fan et al., 2011), pancreas (Hu 
et al., 2003 as cited in Fan et al., 2011) and peripheral blood (Yu et al., 2004 as cited in Fan et 
al., 2011) and the supportive extra-embryonic structures (such as umbilical cord blood (Lu et 
al., 2005 as cited in Fan et al., 2011), umbilical cord (UC) (Fan et al. 2005 as cited in Fan et al., 
2011), amniotic fluid (AF) (Mareschi et al., 2009 as cited in Fan et al., 2011), placenta (In’t 
Anker et al., 2004 as cited in Fan et al., 2011)  and amnion (Bilic et al., 2008 as cited in Fan et 
al., 2011), respectively.  
New efficient stem cells sources would have to exhibit a similary potential to that of ESCs 
and to be highly proliferative or at least easy to harvest in large numbers. Out of these, the 
preferred ones are the BM-derived stem cells or UC-derived stem cells. There are two main 
cell types within the BM: mesenchymal, which are highly proliferative and show a 
propensity for multi-lineage differentiation (Rogers & Casper, 2004) and haematopoietic, 
also promising as multipotential stem cell (Kakinuma, 2003; Hao, 2003 as cited in Rogers & 
Casper, 2004). As mesenchymal cells and blood cells are likely to become potential 
alternatives to ESCs in some clinical situations, umbilical cord blood (UCB) and peripheral 
blood (PB) have started to be more and more regarded as sources of bone-marrow-like stem 
cells due to their easy  harvesting compared to bone marrow (Rogers & Casper, 2004) Cord 
blood is already considered an important source for stem cells, mainly because, different 
from BM, there is no need for a perfect human leucocyte antigen (HLA) match, there is a 
lower risk of graft versus host disease (GVHD) with UCB transplantation than with BM 
transplantation and because UCB has more haematopoietic stem cells per volume than 
peripheral blood or bone marrow (Rogers & Casper, 2004; Barker & Wagner, 2003).  
Consequently, the proliferation, the easy harvesting procedure, the advantages over 
embryonic and adults counterparts and no serious ethical issues are the main points that 
recommend the human cord blood (CB) as the most valuable solution against other stem cell 
sources, as detailed below.  
2. The human umbilical cord: A source of stem cells 
UCB has been widely considered an important stem cell source, because of its many pluses 
as compared with other stem cell sources. CB usually comes as a second choice after 
matched BM or PB but in the case of children suffering from leukaemia it represents the 
main stem cell source for transplant.  (Stanevsky et al., 2009). Moreover, CB is also viewed as 
a primary stem cell source due to annual global human birth rate of more than 100 million a 
year. CB is easily and safely collected by CB banks and preserved as future therapeutic 
genetic material (Arien-Zakay et al., 2010). CB has been more and more considered as good 
alternative for embryonic stem cells lately (Figure 1 A), also because it has proved to contain 
populations of multipotent stem cells which are able to differentiate into a variety of cell 
types, including epithelial, endothelial, myotubes and neural [Harris & Rogers, 2007).  
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The human UC, a connecting tissue of extraembryonic origin, connects the fetus to the 
placenta. Developed during the fifth week of embryogenesis it reaches a final length of 
approximately 60–65 cm and a weight of about 40 g, and has a mean diameter of 1.5 cm in 
normal pregnancies. UC usually comprises two arteries and a vein, all immersed within a 
tissue that interconnects vessels- the so-called Wharton’s jelly (WJ) and enclosed by a simple 
amniotic epithelium. WJ is a mucoid connective tissue abounding in proteoglycans and 
hyaluronic acid (HA), insulating and protecting umbilical vessels from torsion, 
compression, or bending. It is made of embedded stromal cells (Figure 1B). It thus assures a 
constant blood flow between fetus and placenta. (Fan et al., 2011; Malgieri et al., 2010). The 
blood remaining in the umbilical vein after birth is rich in hematopoetic stem and progenitor 
cells, and has been a successful alternative allogeneic donor source in the cure of a variety of 
pediatric genetic, hematologic, immunologic, and oncologic disorders (Broxmeyer et al., 
1989; Gluckman et al., 1997; Han et al., 2003, Kim et al., 2002 as cited in Malgieri at al., 2010). 
Moreover, fresh cord blood is rich in non-hematopoietic stem cells, and also contains 
endothelial cells, mesenchymal stem cells (MSCs) and unrestricted somatic stem cells 
(USCC) (Kogler et al., 2004, 2006; Sensken et al., 2007; Greschat et al., 2008 as cited in 
Malgieri at al., 2010). 
 
 
Fig. 1. Umbilical cord: cross section. (A)Localization of mesenchymal stromal cells. (B) 
Structure of umbilical cord wich contains two arteries and one vein surrounded by 
Wharton`s jelly and amniotic epithelium. 
MSCs are refined as multipotent, undifferentiated cells that can self renew, regenerate 
mesenchymal tissues and blood cells and differentiate into several cell types such as 
chondrocyte, adipocyte, osteocyte, osteoblast, myocyte, cardiomyocyte, neuron-like cell as 
well as into insulin-producing cells (Jiang et al., 2002; Mareschi et al., 2006). There is not 
surprise, then, that they are the focus of regenerative medicine and tissue engineering 
(Arien-Zakay et al.,2010). Despite the fact that BM has been considered the main available 
source of MSCs (Pittenger et al., 1999), it is not always acceptable to use BM –derived cells 
because of the high degree of viral exposure, the significantly decreasing cell number and 
the proliferative/differentiation capacity along with age. Additionally, BM sampling 
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involves a painfully invasive procedure. Therefore, it is of utmost clinical importance in so 
far as the easy accessibility and the reduced morbidity are concerned to try to identify 
alternative sources of MSCs (Malgieri et al., 2010). Anyway, Mitchell et al. (Mitchell et al., 
2003) successfully isolated the matrix cells from porcine and human umbilical cord by 
explants’ culture only in 2003 and, in it was only in the same year that Romanov et al. 
(Romanov et al., 2003) managed to isolate mesenchymal like cells from sub-endothelial layer 
of human umbilical cord vein. Consequently, it is only since 2003 that the umbilical cord-
derived MSCs have started to be extensively researched (Fan et al., 2003). Human UC blood-
derived mesenchymal stem cells (hUCB-MSCs) exhibit ability similar to that of BM-MSCs 
for multi-lineage differentiation (Gang et al., 2004).            
Consequently, UCB has proved a legitimate source for haematopoietic stem cell 
transplantation. Moreover, the development of research and scientific understanding of 
hUCB-MSCs will show that they are a really fascinating source to be used in stem cell 
therapy.  
3. Isolation of MSCs from the umbilical cord 
In recent years, several investigators published protocols for isolating MSCs from the UC 
tissue. These protocols have been developed and adapted based on the region of the cord 




Fig. 2. Schematic illustration of various protocols used to isolate mesenchymal stem cells 
from the umbilical cord tissue. 
The first step in the isolation procedure is represented by the removal of umbilical artery 
and vein followed by the splitting of the cord into smaller segments which are subsequently 
enzymatically digested (Weiss et al., 2006). Another techniques involve isolation methods 
without enzymatic digestions or removal of vessels (La Roca et al., 2009). Several methods 
were also described for the isolation of the cells from the perivascular tissue or the 
subendothelium of the umbilical vein (Covas et al., 2003).  
Currently, the most used protocol is without enzymatic digestion in an explant culture 
approach without removal of umbilical vessels in order to isolate MSC-like cells from the 
whole UC tissue.  
At the beginning, the blood from the umbilical vessels is removed by flushing phosphate 
buffered saline (PBS) through the artery and vein using a sterile syringe coupled to a small 
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tube. The next step is represented by the preservation of UC in a PBS medium enriched with 
5g L-1 glucose, 50 ugmL-1 gentamicin, 2.5 ugmL-1 amphotericin B, 100 U.mL-1 penicillin, and 
100 ugmL-1 streptomycin with the purpose of reducing the risk of contaminations. Then, the 
UC is serially cut first into 10-15 cm long segments and then into 0.5-0.8 cm3 large pieces. 
During the isolation procedure, transfer medium is used to keep the cord and the minced 
pieces moist. Finally, the small pieces are transferred to 25 cm3 flaks and incubated in a 
humidified atmosphere with 5% CO2 in a MEM supplemented with 15% of human serum 
and 50 ugm-1 gentamicin at 37°C which is changed every 48 hours. After 12 days, groups of 
adherent cells from single tissue pieces are observed. At this stage, the UC tissue is removed 
and the adherent cells are harvested by enzymatic treatment. The cell suspension is then 
centrifuged at 100 g for 10 min and the cells are resuspended in MEM supplemented with 
10% human serum and 50 mgmL-1 gentamicin and subcultured at a density of 4000 cells 
cm~2. These culture conditions have demonstrated to support an optimal growth of the cells 
(Wobus et al., 2006).  
Commonly, the isolated cells exhibited a high proliferation potential. For at least 20 
population doublings, the cells can be expanded without loss of proliferative activity and 
viability (Figure 3). After approximately 50 population doublings the process of replicative 
senescence becomes common. At this point, UC-derived cells could be efficiently 
cryopreserved and revitalized in a cryo-medium containing 80% human serum, 10% culture 
medium, and 10 % DMSO.  
 
 
Fig. 3. Isolation of mesenchymal stem cells from umbilical cord: adherent growing 
monolayer of fibroblast-shaped cells after 21st days of culture (Magnification: A-10X, B-40X). 
Depending on the isolation procedures, stem cells characteristics such as proliferation, 
differentiation potential and immunologic properties may be altered. 
4. Characterization of UCSC 
The evaluation of the nature of UCB HSC has demonstrated a higher proportion of primitive 
hematopoietic progenitors in UCB, with superior in vitro proliferative responses and in vivo 
engraftment capacity as compared to adult BM (Lewis et al., 2000; Wynter et al., 1999 as 
cited in Barker & Wagner, 2003) or PB (Barker & Wagner, 2003; Goldberg et al., 2007). Single 
UCB units can reconstitute entire lympho-hematopoietic systems in adults patients 
(Laughlin et al., 2001). In addition, UCB seems more tolerant of HLA mismatches, with less 
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GVHD. These unique biological features are further sustained by the fact that human UCB 
transplantation (UCBT) recipients show reliable myeloid and lymphoid hematopoietic 
reconstitution after myeloablative conditioning with greater than one log lesser nucleated 
cell (NC) dose than is used in BM transplantation (BMT). 
Another unique characteristic of UCB is the reduced alloreactive response as compared with 
that seen with BMT, which is not fully explained. The median CD3+ cell dose of 
8×106 kg−1 in UCB units makes it similar to a BM graft after modest T cell depletion (TCD). 
Such a T cell dose is fully capable of inducing significant GVHD, particularly in the setting 
of HLA mismatch. Therefore, reduced T cell number is insufficient to explain the relatively 
low incidence of severe GVHD with 1–2 antigen-mismatched UCBT. A more likely 
explanation is the functional differences reported with UCB lymphoid cells. These include 
higher levels of CD4+CD45RA+ cells, lower inflammatory cytokine production and 
responses, lower alloantigen and mitogen-specific T cell proliferation, a polyclonal T cell 
receptor repertoire, increased susceptibility to tolerance induction, and differences in NK 
cell and dendritic cell biology (Barker &Wagner, 2003; Canque et al., 2000). 
In recent years, much excitement has been associated with studies that have suggested UCB 
does represent a source of multi-potent stem cells that could be used for generation of non-
hematopoietic tissues. MSCs were isolated from the mononuclear cell fraction of CB using 
various criteria, including adherence to the surface of the culture medium, negative 
expression of hematopoietic markers such as CD34, CD133, CD45, CD14, and positive 
expression of mesenchymal markers such as CD90, CD105, CD73 (Flynn et al., 2007). The 
isolated UCB-MSCs were shown to differentiate into a wide range of cell types including 
bone, cartilage, cardiomyocytes, neural among others. Pre-clinical studies also revealed that 
MSCs from CB support ex vivo expansion and differentiation of haematopoietic 
stem/progenitor cells from CB. These MSCs improved the haematopoietic cells engrafted in 
non-obese diabetic/severe combined immune-deficient (NOD/SCID) mice (Huang et al., 
2007). It is worth mentioning that there is no fully identified unique phenotype for MSCs 
derived from CB, as well as for MSCs from all other origins. This prevents reproducible 
isolation of MSC precursors with predictable potential for development, and their isolation 
and characterisation rely primarily on their ability to adhere to plastic and their ability to 
expand (Arien-Zakay et al., 2010). In the culture, the morphology of hUCB-MSCs 
demonstrates a typical MSCs immunophenothypic markers and fibroblastoid morphology. 
The absence of endothelial CD31 and leukocyte surface markers supports the involvement 
of UCB-MSCs as mesenchymal progenitors. Very important, as it was already mentioned, 
hUCB-MSCs are devoid of hematopoietic and endothelial markers such as CD14, CD28, 
CD31, CD33, CD34, CD45, CD56, CD133, HLA-DR, and for graft versus host disease CD80, 
CD86, CD40, which show that they are suitable for transplantation (Malgieri et al., 2010). 
The comparison between hUCB-MSCs and BM-MSCs showed that hUCB-MSCs share most 
of their immunophenotype with BM-MSCs, including a cluster of differentiating markers, 
neural markers and extracellular adhesion molecules as well as the cell cycle status, the 
adipogenic and osteogenic differentiation capacity and finally the cytokines and 
hematopoietic supportive function (Malgieri et al., 2010). Despite this, recent studies noted 
that there are still several differences between them. Firstly, the fibroblast colony-forming 
units (CFUF) frequency was significantly higher in UCB derived nucleated cells than in BM 
derived nucleated cells, which practically indicated a higher frequency of MSCs in the 
nucleated cells of UCB than in those of BM. Secondly, the proliferation analysis revealed 
that hUCB-MSCs have a faster population doubling time, as compared to BM-MSCs, that 
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not change after 30 passages. UCB-MSCs also had a higher proliferative capacity of in 
comparison with BM-MSCs indicating that hUCB-MSCs may be a novel alternative source 
of human MSCs for clinical applications (Malgieri et al., 2010). Furthermore, Lu et al. (2006) 
noted the absence of HLA-DR expression on hUCB-MSCs and low expression of HLA-ABC, 
known as a hurdle for allogenic cell therapies, which may favour the use of hUCB-MSCs for 
allogenic cell therapy.  
In a still growing set of experiments, another population of CB stroma cells was isolated, 
using the CD45 negative expression and the adherence abilities. These cells were termed 
unrestricted somatic stem cells (USSCs) (Kogler, 2004, 2006). They were reported to 
differentiate in vitro into osteoblasts, chondrocytes, adipocytes and neural progenitors as 
well as in vivo into bone, cartilage, haematopoietic cells and neural and heart tissue (Kim et 
al., 2005; Kogler et al., 2004). Furthermore, it was even suggested that because USSCs can 
easily be committed towards the mesenchymal cell lineage, they may represent an early 
mesodermal progenitor of MSC (Arien-Zakay et al. 2010). 
5. In vitro differentiation potential of UCSC 
5.1 Differential potential into osteogenic, chondrogenic and adipogenic lineages 
HUCB-MSCs hold tremendous promise for tissue engineering and regenerative medicine as 
exposed to appropriate conditions and various factors they can differentiate in vitro along 
several cell lineages (Figure 4) of three germ layers such as the chondrocyte, osteoblast, 
adipocyte, myocyte, cardiomyocyte, endothelium, neuronal, astrocyte, oligodendrocyte 
pancreatic , hepatocyte lineages and others (as further detailed below) (Fan et al., 2011). 
Several researches reported that certain stimuli direct CB-derived MSCs and USSCs to 
differentiate into osteoblasts (Jager et al., 2007 as cited in Arien-Zakay et al., 2010; Kogler et 
al., 2006; Lee et al., 2004 as cited in Arien-Zakay et al., 2010). A recent study comparing the 
cell-mediated remodeling of three-dimensional collagen I/III gels during osteogenic 
differentiation of BM-MSCs and hUCB-MSCs showed that both cell types display all 
features needed for effective bone fracture healing (Schneider et al., 2010). On the contrary, 
comparing the the chondrogenic potential of hBM-MSCS and hUCB-MSCs it was noted that 
hUCB-MSC group had 3-times as much collagen as the hBM-MSC group, which supports 
the former may be a more desirable option for fibro-cartilage tissue engineering (Wang et 
al., 2009 as cited in Fan et al., 2011).  Furthermore, the cell differentiation into chondrocytes 
was significantly augmented by bone-morphogenetic protein (BMP)-4, a mesodermal factor 
known to promote chondrogenesis. Additionally, the successful transformation of hUC 
stroma-derived stem cells into mature adipocytes supports their therapy for esthetic 
purposes (Karahuseyinoglu et al., 2008 as cited in Fan et al., 2011).      
5.2 Differential potential into cardiomyocytes  
Attempts to transdifferentiate CB-MSCs towards cardiomyocytes have yielded different 
results. 5-azacytidine, a chemical analogue of the cytosine nucleoside in the DNA and RNA 
helix, is currently employed to initiate myogenic differentiation. In spite of the fact that 
some researches successfully transformed Wharton’s jelly derived hUC-MSCs into 
cardiomyocytes by 5-azacytidine or cardiomyocyte-conditioned medium and noted a slight 
spontaneous beating (Pereira et al., 2008; Wang et al., 2004 as cited in Fan et al., 2011), others 
failed to generate cardiomyocyte-like cells from hUC-MSCs, either spontaneously or after 
treatment with 5-azacytidine (Martin-Rendon et al., 2008). For instance, Roura et al. (2010) 
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failed to transdifferentiate CB-MSCs towards cardiomyocytes in vitro-the cells did not 
express cardiomyocyte-specific proteins or presence of calcium rhythmic oscillations or 
potential-dependent fluorescence emission after various protocols, including addition of 
chemicals (5-azacytidine and dimethyl sulphoxide), growth factors, Wnt signaling activators 
and direct contact with neonatal rat cardiomyocytes. Similarly, in other studies there wasn’t’ 
any evidence for neocardiomyocyte formation after systemic delivery of CB-mononuclear 
cells, or direct intramyocardial delivery of CB-133+  cardiac membrane cells, suggesting that 
there is a limitation in the potential for differentiation of unmodified CB-derived stem cells 
into cardiomyocytes (Murry et al., 2004). However, MSCs isolated from 
endothelial/subendothelial layers of the human umbilical cord veins have been proved to 
have the potential of transdifferentiating into cardiomyocyte-like cells with typical 
ultrastructure and sarcomers as well as expression of several cardiac-specific genes (Kadivar 
et al., 2006). Further studies are warranted to reduce the discrepancy between these research 
papers. However, they suggest that hUC-MSCs can be chemically transformed into 
cardiomyocytes and considered as a source of cells for cellular cardiomyoplasty. 
 
 
Fig. 4. Umbilical cord mesenchymal stem cell differentiation. 
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5.3 Differential potential into endothelial cells  
Searching for sources with higher availability of endothelial progenitor cells, (Wu et al. 2007) 
cultured hUC-MSCs in an endothelial differentiation medium containing vascular 
endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) hUC-MSCs 
differentiated into endothelial cells as demonstrated by acetylated low-density lipoprotein 
incorporation and expression of endothelial-specific proteins, such as platelet/endothelial 
cell adhesion molecule (PECAM) and cd34 (Wu et al., 2007). In comparison of endothelial 
differentiation of hUC-MSCs and BM-MSCs, some researches noted that hUC-MSCs had 
higher proliferate potential, higher expression of the endothelial-specific markers after 
induction and significantly higher total tubule length, diameter and area in angiogenesis 
assay than those of differentiated BM-MSCs (Chen et al., 2009).  
Current studies have addressed the differentiation capacity of CD133 hematopoietic stem 
cell (HSC), a subset of UCB HSC. In particular, Peichev et al. (2000) have shown that cells 
isolated from CB expressing both CD34 and VEGFR2 (KDR) also expressed CD133. CD133 
was not expressed on mature endothelial cells. The investigators further characterized these 
cells by illustrating their ability to migrate and differentiate into mature endothelial cells 
(Peichev et al., 2000). A subsequent study also demonstrated the differentiation of CB-
derived CD34+ CD133+ cells into endothelial phenotype in vitro (Pesce et al., 2003). 
5.4 Differential potential into neural cells 
During the past decade, numerous in vitro studies have demonstrated the generation of 
neuronal cells from various CB-derived populations. For instance, embryonic stem (ES)-like 
cell population from CB were found to possess neuroglial progenitor morphology and 
primitive neuroglia cell markers (Mcguckin et al., 2004). Chen et al. (2005) detected positive 
expression for antigens typical of brain tissue in other adherent cell subpopulation from CB. 
CB-derived populations purified by antigen expression were also shown to differentiate into 
a neural phenotype. CB-CD133 positive cells (Jang et al., 2004 as cited in Arien-Zakay et al., 
2010) or CD34− CD45− non-haematopoietic stem cells (Habich et al., 2006 as cited in Arien-
Zakay et al., 2010) differentiated into neuronal and glial cells that expressed neuronal and 
astrocyte-specific markers. Moreover, the full range of neural differentiation ability of the 
CB-CD45+ multipotential stem cells was demonstrated by the achievement of positive 
phenotypic and functional markers for dopaminergic neurons, oligodendrocytes and 
astrocytes (Rogers et al., 2007). 
For others, the differentiation potency of hUC-MSCs into neural lineage has attracted 
extensive attention. The pioneering study in the neuronal induction of hUC-MSCs was 
accomplished by Mitchell et al. (2004) using a relatively complex and multi-step neuronal 
induction procedure  previously defined (Mitchell et al., 2004; Woodbury et al., 2000 as cited 
in Fan et al., 2011). In another experiment, hUC-MSCs began to express neuron-specific 
proteins and exhibit retraction of cell body, elaboration of processes, and clustering of cells 
after three days’ induction with neuronal conditioned medium (NCM). Glutamate invoking 
inward current was found in the transformed cells between the 9th and 12th days, which 
suggested that the induced cells differentiated into mature neurons in the post mitosis phase 
at this stage (Fu et al., 2004). Using a three-step neural induction protocol 60% of the 
neuroglial cells transformed from hUC-MSCs were stained positive for microtubule-
associated protein (MAP-2) and 32% stained positive for GFAP. Moreover, some of them 
expressed TuJ-1, synaptophysin and Ǆ-aminobutyric acid (GABA). Expression of neuronal 
markers, such as neuron-specific nuclear protein (NeuN) and MAP2, by induced hUC-MSCs 
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were also observed by other investigators. More specifically, other investigators observed 
that induction with protocol similar to Woodbury et al. (2000) resulted in a lower number of 
cells expressing markers for early neural progenitors (i.e., nestin), however, a greater 
number of cells expressed a mature neural marker for catecholaminergic cells - tyrosine 
hydroxylase (TH) (Ding et al. 2007; Kadam et al., 2009; Weiss et al., 2006 as cited in Fan et al., 
2011). In addition, Fu et al. (2004) also succeeded in transforming hUC-MSCs into 
dopaminergic neurons in vitro through stepwise culture in NCM, sonic hedgehog, and FGF-
8. These dopaminergic neurons were shown to express the rate-limiting catecholaminergic 
synthesizing enzyme, tyrosine hydroxylase and to release dopamine into the medium (Fu et 
al. 2006).   
5.5 Differential potential into hepatocyte-like cells 
Cirrhosis is a consequence of chronic hepatic injury characterized by replacement of liver 
tissue by fibrosis and scar tissue, with no effective therapy currently available. Recent 
developments in stem cell technology have struggled for identifying novel candidate 
sources of liver cells to be used for regenerative purpose. Instead of ESCs with ethical 
debates and safety concern, fetal or adult liver cells encumbered by organ availability, BM-
MSCs plagued with decreased expansion and differentiation capacities in advanced ages 
(Roobrouck et al., 2008), Campard et al. (2008) demonstrated that in vitro expanded UC-
MSCs constitutively expressed markers of hepatic lineage and genes of enzymes involved in 
hepatic metabolism after three steps of full term hepatogenic induction. However, absence 
of some hepatic markers in differentiating UC-MSCs, such as HepPar1 or HNF-4, implied 
that their differentiation did not reach the level of mature hepatocytes (Campard et al., 
2008). A simple one-step induction protocol with hepatocytic growth factor (HGF) and 
fibroblast growth factor-4 (FGF-4) was also proved to be effective in transforming hUC-
MSCs into hepatocyte-like cells expressing the hepatocyte-specific markers albumin (ALB), 
human ǂ-fetoprotein (AFP) and cytokeratin 18 (CK-18) (Zhang et al., 2009 as cited in Fan et 
al.,2011). Further research showed that differentiated hUC-MSCs could store glycogen and 
uptake LDL (Zhang et al., 2009 as cited in Fan et al., 2011). Very recently, UCB derived HSC 
were also induced to hepatocyte like cells under a 2-step protocol with the combination of 
the same two growth factors-HGF and FGF-4. Hepatocyte like cells were observed at the 
end of the protocol (days 14). These differentiated cells were observed to show high 
expression of genes related to hepatocytes (tryptophan 2, 3-dioxygenase [TO], glucose 6-
phosphate [G6P], CK 18, ALB and AFP (Sellamuthu et al., 2011). In addition, the 
differentiated functional hepatocyte-like cells may still retain their low immunogenicity in 
vitro (Zhao et al., 2009), which facilitate the allotransplantation to replace the diseased liver 
cells.  
5.6 Differential potential into skeletal muscles 
The first successful myogenic transformation of a subset of CD105(+)/CD31(-)/KDR(-) cells 
from WJ of UC into elongated, multinucleated cells expressing of Myf5 and MyoD in vitro 
was reported by Conconi et al.(2006).  
5.7 Differential potential into Islet-like clusters 
In the study by Wang et al. (2010) hMSCs from umbilical cord stroma were induced to 
differentiate into insulin-producing cells using differentiation medium. Pancreatic beta-cell 
www.intechopen.com
 
Human Cord Blood-Derived Stem Cells in Transplantation and Regenerative Medicine 
 
31 
development-related genes were expressed in the differentiated insulin-producing cells. 
Differentiated cells' C-peptide release in vitro increased after glucose challenge (Wang et al., 
2010). Another recently published research also showed that WJ- derived hUC-MSCs may 
serve as a promising alternative cell source of transplantable islet-like clusters (Chao et al., 
2008 as cited in Fan et al., 2011). Besides differentiating fresh human UCB into insulin-
secreting cells, Phuc et al. (2011) showed that also MSCs derived from banked cord blood 
(cryopreserved for 1 year) can be differentiated into functional pancreatic islet-like cells in 
vitro. Having in mind their advantages including large potential donor pool, rapid 
availability, low risk of rejection and no risk of discomfort for the donor, hUC-MSCs might 
become an excellent candidate in ǃ-cell replacement therapy of diabetes mellitus. 
6. Immune properties of MSCs and in vivo applications 
Besides their multi-lineage differentiation potential, UC-derived MSCs have been shown to 
have immune suppressive action on lymphocyte proliferation through alloantigen and 
mitogens such as phytohemagglutinin and to reduce the level of proinflammatory cytokines 
such as interferon-y (IFN-y) and tumor necrosis factor-a (TNF-a). These immune-privileged 
and immune-modulator properties, recommend them as ideal candidates for cell-based 
therapies. They fail to induce proliferation of allogeneic lymphocytes in vitro and do not 
induce an immune response when used in allogenic mismatched animal experimental 
models (Devine et al., 2003). Furthermore, they have regulatory effects on several cells of the 
immune system (e.g., T, B, dendritic, and natural killer cells) (DiNicola et al., 2002), prolong 
skin graft survival (Bartholomew et al., 2002) and have been used in clinical applications to 
reduce acute and chronic GVHD (Ringden et al., 2006). It has been demonstrated that UCB-
MSCs can suppress not only the function of mature dendritic cells but also increase the 
portion of regulatory T cells (LeBlanc et al., 2004). This regulation of immune response by 
MSCs is mediated by soluble factors and cell to cell contact mechanisms. Co-culture 
experiments showed that UCMSCs did not induce any proliferation of resting immune cells 
and also suppressed the purified T cells or activated human peripheral blood mononuclear 
cells. 
7. In vivo applications of UCSC 
7.1 Ischemic vascular disease 
7.1.1 Myocardial infarction 
In spite of the fact that the treatment of cardiovascular disease and myocardial infarction has 
benefited over the past 15 years from advances in pharmacologic and intravascular 
intervention to include placement of drug-eluting stents and interventional re-
vascularization, this condition is till associated with significant morbidity and mortality. 
Furthermore, the fact that there still aren't eligible donors for heart transplant candidates, 
combined with the limited ability of endogenous cardiomyocytes to divide and repair 
infarcted myocardium has encouraged the use of stem cell transplantation as adjuvant 
therapy for cardiovascular disease (Abbott & Giordano, 2003; Ramakrisham et al., 2003 as 
cited in Goldberg et al., 2007).  
Both small clinical trials in humans and animal studies employing cellular therapies have 
produced data suggesting the efficacious nature of this modality lately. However, as far as 
patient-derived (adult marrow or mobilized peripheral blood) stem cells are concerned 
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there are distinct disadvantages for their routine clinical application including the need to 
subject the patient to stem cell or large volume BM collection at a time of active 
cardiovascular disease and the needed time for cell culturing for some type of these cells 
(Goldberg et al., 2007). In addition, there is data suggesting that in patients either at high 
risk for future cardiovascular disease events or who have documented coronary disease, the 
body’s endogenous stem cell supply and marrow response may be inadequate, as 
circulating endothelial progenitor cells isolated from patients with increased cardiovascular 
risk and compared to those isolated from healthy subjects are reduced in number and 
demonstrate increased degeneration in vitro (Goldberg et al., 2007; Hill et al., 2003).  
Additional cellular sources such as embryonic and fetal cardiomyocytes have been studied 
as a means to improve the failing myocardium (Ramakrisham et al., 2003 as cited in 
Goldberg et al., 2007). However, besides ethical consideration and possible immune 
rejection, which are common to both lines, there are other several limitations such as the 
potential for malignant transformation and for malignant arrhythmias with respect to 
embryonic stem cells (Abbott & Giordano, 2003; Ramakrisham et al., 2003 as cited in 
Goldberg et al., 2007) as well as limited availability and sensitivity to ischemia of fetal 
cardiomyocytes (Etzion et al., 2001; Ramakrisham et al., 2003 as cited in Goldberg et al., 
2007) that may preclude their clinical application, encouraging consequent search for other 
sources of stem cells.  
Encouraging results were obtained increasingly from in vivo animal trials using CB stem 
cells to rejuvenate infracted myocardium, enhance healing and improve ventricular 
function. It was shown that the human CB mononuclear cells administered into the infracted 
border progressively improved the function of the left ventricle and reduced the size of 
infarction in rats with induced acute myocardial infarction (AMI) (Henning et al., 2004). 
Furthermore, Ma et al., (2005) who experimented with NOD/SCID mice with induced AMI, 
reported migration of CB mononuclear cells to the heart in 50% of the mice. The size of the 
infarct zone thus decreased and collagen deposition, as well as increased capillary density 
were detected, but no myogenesis. Further studies directed towards the ability of UCB 
CD34+ to improve cardiac function in a model of coronary ischemia were carried out by 
Hirata et al. (2005). In these experiments, AMI was induced in conditioned male Wistar rats 
and CB-derived CD34+ cells were injected into the peri-infarct zone. 4 weeks after 
transplantation, reduction of the left ventricular dilation and improvement of the cardiac 
function were reported. Moreover, intramyocardial CB cells survived, localized around the 
vessels of the ischaemic myocardium and capillary density was increased, but only about 
1% of the injected cells were incorporated into the myocardium vessels of the rat, indicating 
that the angiogenic factors released by these cells account for the angiogenesis (Hirata et al., 
2005). Similarly, significantly improved cardiac function, markedly increased capillary and 
arteriole density, and notably decreased apoptotic cells were reported by Wu et al. (2007), 
who investigated the therapeutic potential of hUC-MSCs in a rat myocardial infarction 
model. Moreover, it seems that some of transplanted cells managed to live in the infracted 
myocardium, gathered around arterioles and spread in capillary networks. Noteworthy is 
the fact that some of them exhibited cardiac troponin-T, von Willebrand factor, and smooth 
muscle actin, proving that the damaged myocardium regenerated by cardiomyocytic, 
endothelial, and smooth muscle differentiation of hUC-MSCs in the infracted myocardium 
(Wu et al., 2007). A specific subset of CB- CD34+ cells, the CD34+ KDR+ cell fraction was 
suggested as the factor for angiogenesis and improvement of cardiac function for both 
treatment with mononuclear cells and CD34+ cells (Botta et al., 2004). In a study by Botta et 
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al. (2004), the myocardium of a NOD/SCID mouse was injected with the CD34+ /KDR+ 
double selected fraction, isolated from UCB, immediately after the ligation of the left 
anterior descending artery (LAD). Apoptosis was impaired in this cell population versus 
CD34+ /KDR- cells in extended culture (up to 22 days). The release of VEGF from the 
CD34+ /KDR+ cells is thought to provide an autocrine mechanism for survival. The left 
ventricular end-diastolic pressure decreased as well as the infarct size in the transplanted 
group for a period up 5 months after AMI induction. The treatment with this cell type also 
determined more angiogenesis compared with mononuclear cells or CD34+ (Botta et al., 
2004). Moreover, immunostaining for human nuclei showed localization of human cells 
within cardiomyocytes. However, it was not clear whether the transplanted cells had fused, 
overlapped with or differentiated into cardiomyocytes (Botta et al., 2004; Goldberg et al., 
2007). Similar results were reported by Leor et al. (2006), using another immature CB subset, 
CD133+. CB cells were infused into athymic nude rats with ligated coronary arteries and 
one month after infusion CB cells had migrated, colonized and survived in the infracted 
myocardium, being identified near the vessel walls and in the left ventricular cavity. 
Functionally, the left ventricular fractional shortening improved and the anterior wall 
thickness diminished (Leor et al., 2006). Ma et al. (2006) reported a comparison of CD133+ 
expressing cells from UCB and BM in an AMI model. Selected UCB CD133+ cells were 
injected into injured myocardium of NOD/SCID mice and 4 weeks later the analysis 
illustrated an approximate 30% absolute mortality reduction in UCB CD133+ -treated 
animals versus control. Further histological analysis focusing on capillary density produced 
a 25% increase in this number in cell treated animals versus controls (Ma et al., 2006). In a 
large animal study, Kim et al. (2005) used a porcine model with chronically occluded LAD 
and injected CB USSCs directly into the infracted tissue. The grafted cells were detected in 
the tissue 4 weeks later, the perfusion and wall motion of the infracted area improved 
whereas the scar thickness decreased (Kim et al., 2005). Overall, these studies suggest a 
positive effect of a variety of different UCB-derived cell types including cells expressing 
CD34 and CD133. There are significantly larger numbers of hemangioblasts in UCB which 
have the same efficacy as that of the BM stem cells. After cell transplantation the ejection 
fraction and hemodynamics showed cardiac function improvement. It seems that ex vivo 
long-term cultures do not to affect their ability to increase cardiac function post-infarction 
(Goldberg et al., 2007).  
7.1.2 Buerger’s disease 
MSCs from CB were also proposed for the treatment of hind limb ischemia. In a pre-clinical 
study, ischemia was induced in the hind limb of athymic nude mice by femoral artery 
ligation and human UCB-derived MSCs were transplanted into the ischemic area. Up to 60% 
of the hind limbs were saved in the femoral artery-ligated animals and the human UCB-
derived MSCs were detected by in situ hybridization in the arterial walls of the ischemic 
hind limb in the treated group (Kim et al., 2006). Buerger's disease, also known as 
thromboangiitis obliterans, is a nonatherosclerotic, inflammatory, vaso-occlusive disease, 
characterized as a panangiitis of medium and small blood vessels, including both arteries 
and adjacent veins, especially of the distal extremities (the feet and the hands). No curative 
medication or surgery for this disease has been discovered so far. The efficacy of CB-derived 
MSCs was verified in the treatment of limb ischemia and pain in a clinical case study of 
Buerger’s disease (Kim et al., 2006). HLA-matched human UCB-derived MSCs were 
transplanted into four men with Buerger's disease who had already failed previous medical 
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and surgical therapies. As a result, ischemic rest pain suddenly disappeared from their 
affected extremities, the necrotic skin lesions were healed, the number and size of digital 
capillaries increased and peripheral circulation improved (Kim et al., 2006), indicating that 
human UCB-derived MSC transplantation may be a new and useful therapeutic tool for 
Buerger's disease and similar ischemic diseases.  
7.2 Metabolic diseases 
7.2.1 Diabetes mellitus 
In 2000 there were 150 million people in the world affected by diabetes mellitus (DM) and 
this number is estimated to double in 2025 (Zimmet et al., 2001 as cited in Fan et al., 2011). 
Moreover, in the US there are approximately, 15000 youth newly diagnosed with type 1 DM 
every year (Malgieri et al., 2010). Type 1 DM is the outcome of a cell-mediated autoimmune 
attack against pancreatic ǃ-cells and the autoimmune response precedes the clinical 
diagnosis. When hyperglycaemia appears the autoimmune process is significantly advanced 
due to the fact that 70-80 % of the ǃ-cell mass has been already damaged when the disease 
started (Couri & Voltarelli, 2008 as cited in Arien-Zakay et al., 2010). Therefore, besides tight 
control of blood glucose, self blood glucose monitoring and patient education, which have a 
significant role in the prevention of the development and retard the progression of chronic 
complication, ǃ-cell mass preservation and/or increase are important targets in 
management of type 1 DM. Additionally, the replacement of a patient’s islets is the only 
treatment of type 1 DM that achieves an insulin-independent, constant normoglycaemic 
state and avoids hypoglycaemic episodes ( Bretzel et al., 1993 as cited in Fan et al., 2011). 
Recently, efforts have focused on the use of both autologous and allogenic stem cells as 
sources of new islets, and perhaps more surprisingly, as potential sources of safe and 
effective immunomodulation (Limbert et al., 2008). In vitro and in vivo studies have shown 
that hUCB-derived stem cells and CB-derived MSCs can differentiate into insulin-secreting 
ǃ-cells (Reddi et al., 2010) expressing pancreatic ǃ-cell markers and synthesizing and 
secreting functional islet proteins ( Gao et al., 2008; Parech et al., 2009 as cited in Arien-
Zakay et al., 2010). In the study by Wang et al. (2010) hMSCs from umbilical cord stroma 
were induced to differentiate into insulin-producing cells using differentiation medium. 
Pancreatic beta-cell development-related genes were expressed in the differentiated insulin-
producing cells. Differentiated cells' C-peptide release in vitro increased after glucose 
challenge. Further, in vivo glucose tolerance tests showed that blood sugar levels decreased 
following cells' transplantation into nonobese diabetic (NOD) mice (Wang et al., 2010). 
Another recently published research also showed that WJ- derived hUC-MSCs may be a 
promising source of cells of transplantable islet-like clusters (Chao et al., 2008 as cited in Fan 
et al., 2011). Besides differentiating fresh human UCB into insulin-secreting cells, Phuc et al. 
(2011) showed that also MSCs derived from banked cord blood (cryopreserved for 1 year) 
can be differentiated into functional pancreatic islet-like cells in vitro. These results suggest 
that if human MSCs, especially MSCs from banked cord blood of diabetes patients 
themselves can be isolated, proliferated, differentiated into functional pancreatic islet-like 
cells, and transplanted back into them (autologous transplantation), their high-proliferation 
potency and rejection avoidance will provide one promising therapy for diabetes (Phuc et 
al., 2011). Recent reports evidenced also that WJ derived-MSCs possess immunomodulatory 
activities (acting on both innate and acquired immunity effectors) which should reduce the 
immunogenicity of transplanted cells, thus decreasing rejection. Moreover it has been 
proposed that MSC administration should be used to alleviate the autoimmune processes 
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which lead to the destruction of beta cells (Anzalone et al., 2010). Besides reducing blood 
glucose levels and increasing survival in mouse models of type 1 and type 2 DM (Ende et 
al., 2004 as cited in Arien-Zakay et al., 2010), CB cell infusion was also proved to improve 
renal abnormalities and neuropathy caused by DM, suggesting a regenerative action in renal 
parenchyma and nerves (Ende et al. 2004; Naruse et al., 2005 as cited in Arien-Zakay et al., 
2010). Autologous hUCB-MSCs are currently being evaluated in a clinical trial to treat type 1 
DM in children (Haller et al., 2008). Moreover, autologous CB infusion in subjects with type 
1 DM has been proved not only safe but also efficient by Haller et al. One-year follow-up 
suggest that autologous CB transfusion is safe and provides some slowing of the loss of 
endogenous insulin production in the treated children. However, the lack of significant 
adverse events associated with the study seems to have been the most important result. 
Nevertheless, we need broader randomized studies as well as 2-year post-infusion follow-
up of this cohort to establish whether autologous CB-based approaches can be employed to 
decrease the endogenous insulin production in children with type 1 DM. This current study 
is still recruiting children with newly diagnosed type 1 DM, who also have their own CB 
deposited in a CB bank, for phase II trials. Consequently, the treatment of auto-immune 
type 1 and 2 DM may greatly benefit from the two positive effects of CB, namely its 
regenerative abilities and immunomodulatory function (Arien-Zakay et al., 2010).  
7.2.2 Hurler syndrome 
The mucopolysaccharidoses (MPSs) are inherited metabolic disorders (IMDs) caused by 
single-gene defects leading to progressive cellular accumulation of glycosaminoglycans 
(GAGs) and damage to multiple organs, including the central nervous, musculoskeletal or 
cardiorespiratory systems. Hurler syndrome, the most severe form, is the prototypical 
model. At present, while available for some conditions, exogenous enzyme replacement 
therapy is unable to correct cognitive and central nervous system disease because of its 
inability to cross the blood-brain barrier. In contrast, allogeneic HSC transplantation (HSCT) 
allows donor-derived, enzyme-producing cells to migrate to the brain and other organs to 
provide permanent enzyme therapy and thus help somatic organs, improve neurocognitive 
function and quality of life, and prolong survival, particularly when performed early in the 
course of the disease. HSCT may also mediate non-hematopoietic cell regeneration or repair. 
Bone marrow has been the graft source in the past. However, in the last 5 years many 
patients have been treated with unrelated donor (URD) UCBT, allowing rapid and increased 
access to transplantation with favorable outcomes (Prasad & Kurtzberg, 2010 a, 2010 b). 
Sustaining this, CB transplantations led to improved neurocognitive performance and 
decreased somatic features of Hurler’s syndrome (Staba et al., 2004 as cited in Arien-Zakay 
et al., 2010) and therefore it might be considered as a preferred source of cells for treatment 
of this disease, as recently suggested after risk factor analysis of patients from the European 
Group for Blood and Marrow Transplantation (EBMT) ( Boelens et al., 2007, 2009].    
7.3 Heart valve replacement 
Currently used replacements in cardiovascular surgery are made of foreign materials with 
well known disadvantages such as thrombo-embolic complications, infections, loss of 
functional and biological properties, and others. (Breymann et al., 2006). Tissue engineering 
of viable, autologous cardiovascular constructs with the potential to grow, repair, and 
remodel represents a promising new concept for cardiac surgery, especially for pediatric 
patients with congenital cardiac defects. Currently, vascular myofibroblast cells (VC) 
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represent an established cell source for the construction of cardiovascular tissue. Cell 
isolation requires the invasive harvesting of venous or arterial vessel segments before 
scaffold seeding, a technique that may not be preferable, particularly in pediatric patients. 
(Kadner et al., 2002). It has been increasingly shown that, considering their excellent growth 
properties and tissue formation with biomechanical properties approaching native tissue in 
vitro, hUC cells seem to represent a promising alternative autologous cell source for 
cardiovascular tissue engineering, offering the additional benefits of using juvenile cells and 
avoiding the invasive harvesting of intact vascular structure (Breymann et al., 2006). 
Hoerstrup et al. (2002) successfully constructed living, autologous pulmonary artery 
conduits tissue with hUC cells (Hoerstrup et al., 2002 as cited in Fan et al., 2011), while 
another group published their successful attempt in tissue engineering of autologous human 
heart valves using cryopreserved vascular umbilical cord cells (Sodian et al., 2006). These 
results show that establishing autologous human cell banks for pediatric patients diagnosed 
intrauterinely with congenital defects and likely to need heart valve replacement in the early 
years of life is of utmost importance (Sodian et al., 2006). Thus, tissue engineering of 
autologous heart valves with the potential to grow and to remodel is likely to become a 
fructuous idea. Sustaining these observations, more recently, the same authors described the 
successful use of cryopreserved umbilical cord blood-derived CD133(+) cells as a single cell 
source for the tissue engineering of viable human heart valves (Sodian et al., 2006).  
7.4 Neurological disorders 
7.4.1 Stroke 
Ischemic stroke with its immediate neurological injury due to interruption of blood flow to 
the brain, is a medical emergency of utmost severity: it can trigger severe functional defects 
in the brain, permanent neurological damage, complications and even death. If it is not 
quickly diagnosed and treated, it can turn the patient into a huge social and economic 
burden. The treatment of the stroke has been under constant research by several novel 
neuron-restorative approaches and it has become the main target for stem cell therapy. In 
this respect, a variety of stem cells are currently being studied in this research for best 
implant resource (Fan et al., 2011). 
The ability and safety of CB and derived cell populations to protect against neurological 
deficits was proved in vivo in a variety of injuries models. The first evidence of a therapeutic 
effect of hUCB came from an experiment where rat was used for middle cerebral artery (MCA) 
occlusion to induce ischemia. Intravenous administration of hUCB resulted in improved 
behavioral deficits after stroke in rats (Sanberg et al., 2005). In another recently study the 
researchers examined the effects of hUCB-MSCs in canine thromboembolic brain model 
(Chung et al., 2009). Cerebral ischemia was induced through occlusion of the MCA by injecting 
thrombus emboli into 10 beagles. Infarct volume decreased 1 day after hUCB- MSCs were 
transplanted through the basilar artery in canine cerebral ischemia whereas infarct volume 
was increased in the control groups (Chung et al., 2009). Transplanted hUCB-MSCs were 
differentiated into neurons and astrocytes in and around endothelial cells and expressed 
neuroprotective factors, such as brain-derived neurotrophic factor (BDNF) and VEGF, at 4 wk 
transplantation. Additionally, Jeong et al. reported that transplantation of hUCB- MSCs into 
contralateral regions of injured rat brain at 7 day after injury resulted in significant behavioral 
improvement and that PKH26-labelled hUCB- MSCs differentiated into neural cells at the 
injured site 4 wk after transplantation (Jeong et al., 2006 as cited in Kim et al., 2010). Similarly, 
Chen et al. (2001) demonstrated in a medial carotid artery occlusion model of stroke that upon 
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CB intravenous administration, many of the physical and behavioral deficits associated with 
this disease were improved (Chen et al., 2001 as cited in Arien-Zakay et al., 2010). These 
observations were further supported by other groups, monitoring the dependency of the 
conferred beneficial effects in the CB cell dose (Vendrame et al., 2004 as cited in Arien-Zakay et 
al., 2010) and the timing of transplantation after injury (Newcomb et al., 2006 as cited in Arien-
Zakay et al., 2010). As mechanisms, the observed beneficial effects afforded by CB therapies 
were suggested to include reduced inflammation (Vendrame et al., 2006 as cited in Arien-
Zakay et al., 2010), apoptotic protection and a combination of trophic actions and nerve fibre 
reorganization (Xiao et al., 2005 as cited in Arien-Zakay et al., 2010). This observation is 
suggested to be mediated via the release of growth and repair factors triggered by anoxia 
(Newman et al., 2006 as cited in Arien-Zakay et al., 2010) as was explored by Arien-Zakay et al. 
(2009) in vitro, who showed that CB-derived progenitors confer protection towards an insulted 
neuron by a mechanism involving the release of antioxidants and neurotrophic and angiogenic 
factors (Arien-Zakay et al., 2009). In another experiment approximately 1*106 clonally 
expanded hUCB-MSCs were transplanted into the cortex of MCA occlusion rat models. 
Consequently, significant improved neurological function as well as considerably increased 
cortical neuronal activity was observed. The transplanted hUCB-MSCs migrated towards the 
ischemic boundary zone and differentiated into glial, neuronal, doublecortin+, CXCR4+ and 
vascular endothelial cells. Moreover, hUCB-MSCs transplantation promoted the formation of 
new vessels to increase local cortical blood flow in the hemispheric and significantly increased 
expression of neurotrophic factors (Ding et al., 2006 as cited in Fan et al., 2011). It was 
hypothesized that modulation by stem cell-derived macrophage/microglial interactions and 
increased ǃ1-integrin expression might enhance the angiogenic architecture as well as 
plasticity of the ischemic brain after the implantation of hUCB-MSCs (Ding et al., 2006 as cited 
in Fan et al., 2011). Koh et al. also noted improved neurobehavioral function, reduced infarct 
volume and increased nestin-positive endogenous stem cells in the hippocampus after 
transplantation of 6*105 hUCB-MSCs into the damaged hemisphere of immunosuppressed 
ischemic stroke rats (Koh et al., 2008 as cited in Fan et al., 2011), but only few transplanted 
MSCs expressed detectable levels of neuron-specific markers. The authors believed that 
improvement in behavioral function might be connected to the neuroprotective effects of 
hUCB-MSCs which resulted in increase of endogenous neurogenesis and reduction of infarct 
volume rather than the formation of new networks between host neurons and the implanted 
hUCB-MSCs (Koh et al., 2008 as cited in Fan et al., 2011). In agreement with these results, other 
investigators also observed that transplanted hUCB-MSCs survived for at least 5 weeks in the 
ischemic brain, significantly reduced injury volume and neurological functional deficits of the 
subjected rats, widely incorporated into cerebral vasculature with partly differentiation into 
endothelail cells, and substantially increased vascular density in ipsilateral hemisphere of 
stroke. It seems that angiogenesis can thus mediate the mechanism for neurological functional 
recovery after hUCB-MSCs transplantation (Liao et al., 2009 as cited in Fan et al., 2011) and 
that transplantation of hUCB-MSCs can be useful in clinical trials for ischemia. However, there 
are serious issues involved, such as the route of transplantation, type of injected cells (hUCB vs 
hUCB-MSCs) and timing of transplanatation when using stem cell therapy with hUCB-MSCs.            
7.4.2 Spinal cord injuries 
The consequences of spinal cord injury (SCI), one of the major disabilities which clinical 
rehabilitation settings face, are: loss of neurons, degeneration of axons, formation of glial 
scar, and severe functional impairment (Hu et al., 2010). It also involves many negative 
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factors in that the patients suffer from motor and sensory impairments as well as many 
other complications during their lifetimes. The restoration of damaged spinal cords has been 
under many clinical trials during the last two decades but the pharmacological therapies 
used in clinical settings are few and have limited effects on the regeneration, recovery speed, 
or retraining of the spinal cord (Hyun & Kim, 2010). Due to their ability to differentiate into 
neural cell lines replacing non functional tissue, stem cells have attracted the interest of 
researches. Efforts have been made to establish new synapses and provide a conducive 
environment. This involved grafting cells from autologous and fetal sources; including 
embryonic or adult stem cells, Schwann cells, genetically modified fibroblasts, bone stromal 
cells, and olfactory ensheathing cells and combinations/ variants thereof (Sobani et al., 2010) 
as well as umbilical cord blood cells (Zhao et al., 2004 as cited in Fan et al., 2011). The 
potential of transplanted CB and derived populations for the treatment of SCI is under 
investigation because of their advantages in comparison with other stem cell sources. It was 
reported that the result of the transplantation of both CB whole fraction and derived CD34 
cells was the localization of these cells around the site of injury and improved functional 
recovery (Nishio et al., 2006; Saporta et al., 2003 as cited in Arien-Zakay et al., 2010). 
Furthermore, the transplantation of hCB in a spinal cord-injured female patient was 
associated with improved sensory perception and mobility, both morphologically and 
functionally and regeneration of the spinal cord at the injured site and some of the cauda 
equine below it, as shown by computed tomography (CT) and magnetic resonance imaging 
(MRI) (Kang et al., 2005 as cited in Arien-Zakay et al., 2010). Kuh et al. studied the effects of 
transplanted HUCBs ± BDNF on moderate degree spinal cord injured rats. The HUCBs 
transplanted group improved, more than the control group at every week after 
transplantation, and also, the BDNF enabled an improvement of the Basso, Beattie and 
Bresnahan (BBB) locomotion scores since the 1 week after its application. 8 weeks after 
transplantation, the HUCBs with BDNF transplanted group had more greatly improved BBB 
scores, than the other groups.  Additionally, the transplanted HUCBs were differentiated 
into various neural cells. The HUCBs and BDNF each have individual positive effects on 
axonal regeneration. The HUCBs can differentiate into neural cells and induce motor 
function improvement in the cord injured rat models. Especially, the BDNF has effectiveness 
for neurological function improvement due to axonal regeneration in the early cord injury 
stage. The authors concluded that the HUCBs and BDNF have recovery effects of a 
moderate degree for cord injured rats (Kuh et al., 2005). Phase I/II clinical trials are in 
progress in the China Spinal Cord Injury Network (http://www.clinicaltrials.gov), aiming 
to determine the feasibility, safety, efficacy and optimal dose of CB mononuclear cell 
transplantation as a method to treat patients with chronic SCI (Arien-Zakay et al., 2010). Due 
to their high ability to differentiate into nerve like cells hUCB-MSCs hold great promise as 
tools for understanding development and as therapeutic agents for spinal cord injury. 
Transplantation of hUCB-MSCs into the injured spinal cord may have the following 
functions-: compensation for demyelination; removal of inhibition; promotion of axonal 
regeneration; direction of axons to appropriate targets and lost cells replacement  (Malgieri 
et al., 2010). A promising research reported by Yang et al. (Yang et al., 2008 as cited in Fan et 
al., 2011) provided evidence that transplantation of WJ-derived hUC-MSCs was an effective 
strategy to promote the regeneration of corticospinal fibers and locomotor recovery after 
spinal cord transaction in the rat. The results were as follows: several weeks after 
transplantation of hUC-MSCs, significant improvements in locomotion and fewer astrocytes 
in the lesion site, activated microglia in rostral and caudal stumps of the lesion as well as 
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increased numbers of regenerated axons in the corticospinal tract and neurofilament –
positive fibers around the lesion site were observed as compared with the control group 
(Yang et al., 2008 as cited in Fan et al., 2011). Moreover, transplanted hUC-MSCs survived as 
long as 16 weeks, migrated from the implantation site for about 1.5 mm in the caudal 
direction of the rostrocaudal axis and produced large amounts of human neutrophil-
activating protein-2, neurotrophin-3 ( NT-3), bFGF and VEGF receptor 3 in the host spinal 
cord, which may help spinal cord repair (Yang et al., 2008 as cited in Fan et al., 2011). The 
regeneration of several corticospinal axons after transplantation of hUC-MSCs is likely to be 
sustained by the release of more cytokines or growth factors from the undifferentiated stem 
cells rather than differentiation of these cells into neuronal or glial cells. The authors also 
believe that the implanted hUC-MSCs are able to modulate the activities of microglia and 
reactive astrocytes (Yang et al., 2008 as cited in Fan et al., 2011). In tight connection with this, 
Zhang et al. (2009) noted that in the case of WJ cells-derived neurospheres transplanted in 
combination with BDNF into transected spinal cord rats, the number of survivor grafted 
cells was very small while BBB scores and axonal regeneration significantly increased and 
reduced cavitations were noticed. These results might be explained through the axonal 
regeneration and neuroprotective action activated by the grafted cells (Zhang et al., 2009 as 
cited in Fan et al., 2011). In another recent study, the treatment with hUC-MSCs proved to 
facilitate functional recovery of hindlimb locomotor function after traumatic spinal cord 
injury in rats, at 5 wks after transplantation. This recovery was accompanied by increased 
length of neurofilament-positive fibers and increased numbers of growth cone-like 
structures around the lesion site. Transplanted hUC-MSCs survived, migrated over short 
distances, and produced large amounts of glial cell line-derived neurotrophic factor and 
neurotrophin-3 in the host spinal cord. There were fewer reactive astrocytes in both the 
rostral and caudal stumps of the spinal cord in the hUC-MSCs group than in the control 
group (Hu et al., 2010). Mesenchymal stem cells can also differentiate into Schwann-like 
cells. Yan-Wu et al. (2011) induced hUC-MSCs in vitro into neurospheres constituted by 
neural stem-like cells, and further into cells bearing strong morphological, phenotypic and 
functional resemblances with Schwann-like cells. These HUMSC-derived Schwann-like cells, 
after grafting into the injured area of the rats' SCI, had a partial therapeutic effect in terms of 
improving the motor function. Furthermore, significant improvement in rats treated by 
Schwann-like cell grafting combined with NT-3 administration was demonstrated in the 
behavioral test as compared with that in animal models received the cell grafting only, 
suggesting that this combined administration may represent a new strategy of stem cell 
therapy for spinal cord injury (Yan-Wu et al., 2011). Taking into account these encouraging 
pre-clinical and clinical trials, reporting improvement of neurological deficits together with 
the increasing amount of data on the differentiation of CB-populations into a variety of 
neuronal phenotypes it may be assumed that CB will become an important factor for 
treatment of neurological illnesses.  
7.4.3 Parkinson’s disease 
Several studies also investigated the CB therapeutic potential in neurodegenerative diseases, 
including Parkinson’s disease (PD), Alzheimer’s disease and amyotrophic lateral sclerosis. 
PD is a neurodegenerative disorder characterized by the progressive loss of striatal 
dopaminergic function. To date, a variety of stem cells have been explored to find a 
promising therapy for this unsatisfactorily treated disease in clinical settings (Yasuhara & 
Date, 2007 as cited in Fan et al., 2011). Fu et al. (2006) showed that in vitro  hUC-derived 
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MSCs transformed into dopaminergic neurons expressing the rate-limiting 
catecholaminergic synthesizing enzyme, thyrosine hydroxylase and releasing dopamine into 
the medium (Fu et al., 2006). Transplantation of these dopaminergic neurons into the 
striatum of Parkinsonian rats could partially relieve the lesion-induced amphetamine-
evoked rotation, indicating an amelioration of motor deficits. Similar results were 
demonstrated by Weiss et al. (2006), who also treated rat models affected by PD with hUC-
MSCs. The transplantation of approximately 1,000 undifferentiated  hUC-MSCs into 
striatum of hemiparkinsonian rats without immune suppression produced an amelioration 
in apomorphine-induced rotations in the pilot test without evidence of formation of brain 
tumors as well as a frank host immune rejection response. The hUC-MSCs produced 
significant amounts of glial cell line-derived neurotrophic factor (GDNF), one of the most 
potent trophic factors for dopaminergic  neurons and FGF (Weiss et al., 2006 as cited in 
Arien-Zakay et al., 2010). More importantly, the TH-positive DA neurons in the substantia 
nigra (SN) and ventral tegmental area (VTA) showed a valid correlation between the 
number of cells and the number of apomorphine-induced rotations. Therefore, the 
behavioral recovery of PD model animals may contribute to rescue of the degenerating DA 
neurons in the SN and VTA (Weiss et al., 2006 as cited in Arien-Zakay et al., 2010). It 
appears that Li et al. (2010) are the first who described the induction of human umbilical 
vein mesenchymal stem cells (HUVMSCs) into dopaminergic-like cells. In their study, 
HUVMSCs were induced in vitro into neurospheres constituted by neural stem-like cells, 
and further into cells bearing strong morphological, phenotypic and functional 
resemblances with dopaminergic-like cells. These HUVMSC-derived dopaminergic-like 
cells, after grafting into the brain of a rat model of PD, showed a partial therapeutic effect in 
terms of the behavioral improvement. Moreover, nerve growth factor (NGF) administration 
significantly promoted the survival of the grafted cells in the host brain and enhanced the 
content of dopaminergic in the local brain tissue and behavioral test demonstrated a 
significant improvement of the motor function of the PD rats after dopaminergic-like cell 
grafting with NGF administration as compared with that of rats receiving the cell grafting 
only, which might indicate this combination as a good and new strategy of stem cell therapy 
for PD (Li et al., 2010).          
7.4.4 Amyotrophic Lateral Sclerosis (ALS) 
Stem-cell transplantation is an attractive strategy for neurological diseases and early 
successes in animal models of neurodegnerative disease generated optimism about restoring 
function or delaying degeneration in human beings (Silani et al., 2004). Considering the lack 
of effective drug treatments for amyotrophic lateral sclerosis (ALS), and compelling 
preclinical data, stem-cell research has highlighted this disease as a candidate for stem-cell 
treatment. In a mouse model of ALS, CB cells transplantation resulted with delayed disease 
progression and improved survival of diseased mice, while the transplanted cells survived 
10-12 weeks after infusion entering regions of motor neuron degeneration in the brain and 
spinal cord (Garbuzova-Davis et al., 2003 as cited in Arien-Zakay et al., 2010), as monitored 
according to transplanted cell dose (Garbuzova-Davis et al., 2008 as cited in Arien-Zakay et 
al., 2010). ALS may also benefit from combined gene/stem-cell approaches. In the study by 
Rizvanov et al. (2011), mononuclear fraction of hUCBCs were transfected by electroporation 
with dual plasmid constructs, simultaneously expressing VEGF(165) and human fibroblast 
growth factor 2 (FGF(2)) (pBud-VEGF-FGF(2)). These genetically modified hUCBCs were 
injected retro-orbitally into presymptomatic ALS transgenic animal models ((G)93(A) mice). 
www.intechopen.com
 
Human Cord Blood-Derived Stem Cells in Transplantation and Regenerative Medicine 
 
41 
The report results demonstrated that genetically naïve hUCBCs may differentiate into 
endothelial (CD34+) and microglial (iba1+) cells; however when over-expressing VEGF-
FGF(2), hUCBCs transform into astrocytes (S100+). Autocrine regulation of VEGF and 
FGF(2) on hUCBCs, signal molecules from dying motor neurons in spinal cord, as well as 
self-differentiating potential may provide a unique microenvironment for the 
transformation of hUCBCs into astrocytes that eventually serve as a source of growth factors 
to increase the survive potential of surrounding cells in the diseased regions (Rizvanov et 
al., 2011).  
7.4.5 Alzheimer’s disease 
Alzheimer's disease (AD) is a proeminent neurodegenerative disease, marked clinically by 
insidious dementia.  The neuropathological hallmarks of AD include the presence of 
extracellular amyloid-beta peptide (Abeta) in the form of amyloid plaques in the brain 
parenchyma and neuronal loss. The mechanism associated with neuronal death by amyloid 
plaques is unclear but oxidative stress, glial activation and inflammatory changes have been 
implicated (Lee et al., 2010a, 2010b). The umbilical cord blood stem cells have been studied 
also in AD and they were shown to markedly diminish the beta-amyloid plaques and 
associated astrocytosis in an AD mouse model (Nikolic et al., 2008 as cited in Arien-Zakay et 
al., 2010). In addition, two very recent studies have demonstrated that hUCB-MSCs can be 
an efficient potential therapeutic agent in AD.  Therefore, transplanted  hUCB-MSC  into 
amyloid precursor protein (APP) and presenilin1 (PS1) double-transgenic mice significantly 
improved spatial learning and memory decline and dramatically reduced amyloid-beta 
peptide (Abeta) deposition, beta-secretase 1 (BACE-1) levels and tau hyperphosphorylation. 
Interestingly, these effects were associated with reversal of disease-associated microglial 
neuroinflammation, as evidenced by decreased microglia-induced proinflammatory 
cytokines, elevated alternatively activated microglia, and increased anti-inflammatory 
cytokines. These results lead us to suggest that hUCB-MSC produced their sustained 
neuroprotective effect by inducing a feed-forward loop involving alternative activation of 
microglial neuroinflammation, thereby ameliorating disease pathophysiology and reversing 
the cognitive decline associated with Abeta deposition in AD mice (Lee et al., 2010 a). 
Moreover, the same authors examined in vitro the potential impact of hUCB-MSCs 
treatment on neuronal loss using a paradigm of cultured hippocampal neurons treated with 
Abeta, confirming that hUCB-MSCs co-culture reduced the hippocampal apoptosis induced 
by Abeta treatment. Furthermore, in an acute AD mouse model to directly test the efficacy 
of hUCB-MSCs treatment on AD-related cognitive and neuropathological outcomes, they 
shown that markers of glial activation, oxidative stress and apoptosis levels were decreased 
in AD mouse brain. Interestingly, hUCB-MSCs treated AD mice demonstrated cognitive 
rescue with restoration of learning/memory function (Lee et al., 2010 b). 
7.4.6 Infantile cerebral paresis and other cerebral impairments 
Traumatic brain injury is also a potential target for treatment using CB cells as it was first 
described by Lu et al. (2002) in a rat model. The transplanted cells migrated into the site of 
brain lesion and a decrease of neurological damage was documented (Lu et al. 2002 as cited 
in Arien-Zakay et al., 2010).  Moreover, brain damage around birth may trigger lifelong 
neurodevelopmental deficits and cerebral palsy is estimated to affect 10 000 infants 
annually. Brain damage of the hypoxic-ischemic kind around birth is also treatable with CB 
cells. Using brain-damaged neonatal rats, Meyer et al. (2006) observed that the neurological 
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effects of cerebral palsy were corrected- spastic paresis was largely alleviated and CB 
mononuclear cells were incorporated in the lesion brain area without obvious signs of 
transdifferentiation (Meyer et al., 2006 as cited in Arien-Zakay et al., 2010). The feasibility of 
CB collection, preparation and autologous infusion in babies born with signs of brain injury 
is now being tested in a pilot study conducted by Duke University 
(http://www.clinicaltrials.gov) (Arien-Zakay et al., 2010).     
7.5 Hemoglobinopathies. Fanconi anemia 
Allogeneic stem cell transplantation is the only curative option for patients with hereditary 
bone marrow failure syndromes. But because nearly two-thirds of patients requiring HSCT 
will not have a suitable related donor, the applicability of HSCT to larger numbers of 
patients has been augmented with the increasing availability of unrelated donors. Presently, 
alternative HSC sources include unrelated donor (URD) bone marrow (BM) or peripheral 
blood stem cells (PBSC) and unrelated donor umbilical cord blood (UCB). While URD BM 
and PBSC transplants have a proven track record of success, the search process takes 3-4 
months, which is often longer than patients with high risk disease can wait. Despite nearly 
13 million registered volunteer donors worldwide, nearly half of patients still do not have a 
closely HLA-matched donor. The applicability of HSCT markedly expanded with the 
introduction of UCBT, particularly for racial and ethnic minorities (Smith & Wagner, 2009). 
The first related donor UCBT was performed in 1988 (Gluckman et al., 1989 as cited in 
Barker & Wagner, 2003) and the first URD UCBT in 1993. Since those first reports, it has 
become clear that UCB is a safe and effective source of HSC for transplant. Moreover, the 
demonstration that hematopoiesis could be reliably reconstituted after myeloablative 
conditioning prompted the development of repositories of banked, HLA-typed UCB. With 
approximately 350,000 units banked worldwide (http://www.bmdw.org), the addition of 
UCB to the available stem cell sources makes it possible for nearly everyone who requires an 
HSCT to have a suitable donor available (Smith & Wagner, 2009). Sustaining this, a very 
recent multicenter, retrospective study, based on data reported to the Eurocord Registry 
about patients with hereditary bone marrow failure syndrome (other than Fanconi anemia) 
who underwent umbilical cord blood transplantation showed that related UCBT is 
associated with excellent outcomes while increasing cell dose and better HLA matching 
might provide better results in unrelated UCBT (Bizzeto et al., 2011).  
Fanconi anemia (FA) is a rare autosomal recessive disease characterized by excessive 
chromosomal breakage, congenital abnormalities, progressive bone marrow failure and a 
predisposition to leukemia and epithelial malignancies (Smith AR & Wagner JE, 2009). The 
hematopoietic stem cell transplantation is the only curative treatment of this disease 
(Bielorai et al., 2004).  
The first CB transplant was performed in 1988 in a patient with Fanconi anemia. The donor 
was his HLA-identical sister who was known by pre-natal diagnosis to be HLA identical 
and not affected by the Fanconi mutation. To date, there have been no formal comparisons 
between the alternative donor sources. As with hemoglobinopathies, URD transplant 
remains the gold standard until retrospective or prospective comparative trials can be 
performed. However, for patients who do not have an HLA-matched donor or who cannot 
wait the time it takes to complete a donor search, UCB is a reasonable alternative (Smith & 
Wagner, 2009). 
More comparative studies are needed before definitive conclusions can be made in 
nonmalignant diseases, but the available data indicate UCB as a feasible alternative HSC 
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source in most patient populations. In general, though, 8/8 HLA-matched BM remains the 
‘gold standard’ for alternative donor HSCT, but UCB should be considered a reasonable 
option in those that do not have such a donor available and for those in whom the time to 
transplant is critical, such that waiting for an URD BM would not be in the best interest of 
the patient. Current practice has been to select the UCB unit that is 0-2 HLA antigen-
mismatched with the patient with the highest cell dose. Further efforts focused on 
increasing the number, HLA diversity and quality of stored UCB units as well as addressing 
cell dose limitations using strategies, such as double UCB transplant and ex vivo expansion 
of a single unit are needed to continue to advance the field of UCBT (Barker & Wagner, 
2003; Smith &Wagner, 2009). 
7.6 Hematological malignancies 
Hematological malignancy is the most common indication for allogeneic HSCT in both 
children and adults. The choice of HSC source depends on both patient and disease 
characteristics and the urgency of the transplant. Because of the rapid availability of units, 
UCB is a particularly attractive option (Smith & Wagner, 2009). 
7.6.1 In children 
Infant leukemia is a particularly challenging form of leukemia to treat and the decision of 
whether to treat with intensive chemotherapy or to proceed with URD transplant when a 
suitable related donor is not available is a difficult one. 
On behalf of the Center for International Blood and Marrow Research (CIBMTR), Eapen et 
al. (2007) recently reported the outcomes of 785 children with acute leukemia comparing 
outcomes in recipients of UCB (n=503) and URD BM (n=282). The most notable finding was 
that UCB compared favorably to the ‘gold standard’ of 8/8 allele-matched unrelated BM. In 
fact, the 5-year leukemia-free survival (LFS) was similar after 8/8 matched unrelated BM 
(MUBM), mismatched unrelated bone marrow (MMUBM) and mismatched UCB (MMUCB) 
with higher survival in recipients of matched UCB (MUCB). The incidence of acute and 
chronic GVHD was similar between the groups. While treatment-related mortality (TRM) 
was higher after two-antigen MMUCB, a lower risk of relapse resulted in comparable 
survival outcomes for this cohort. This research was unique in that UCB was compared to 
the present day standard of allele-level HLA-matched BM donors. These findings support 
the use of HLA-matched or -mismatched UCB in children with high risk acute leukemia 
who need transplantation. (Eapen et al 2007 as cited in Smith &Wagner, 2009). 
7.6.2 In adults 
In contrast to the outcomes in children, HSCT in adults is typically associated with higher 
risks of GVHD, infections, delayed immune reconstitution and increased TRM, partly 
related to a higher likelihood of comorbidities at the time of transplant. In contrast to 
children, use of UCB in adults has been more restricted due to cell dose limitations. The 
safety and feasibility of UCBT in adults with hematological malignancies was first reported 
in 2004 (Laughlin et al., 2004; Rocha et al., 2004 as cited in Smith &Wagner, 2009). 
The outcomes in 1240 adults (148 UCB, 243 MUBM, 111 MMUBM, 518 matched PBSC 
MPBSC and 210 mismatched PBSC MMPBSC) were examined and the results were 
published recently in an abstract on behalf of the CIBMTR (Eapen et al., 2008 as cited in 
Smith &Wagner, 2009). Contrary to the previous data (Laughlin et al., 2004; Rocha et al, 2004 
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as cited in Smith & Wagner, 2009), all unrelated donor BM and PBSC grafts were matched at 
allele level for HLA-A, -B, -C, and –DRB1. In this analysis, TRM was lower and LFS higher 
when MUBM and MPBSC were used as compared to the other sources, suggesting that 
these graft sources are preferred when available and time permits. However, partially HLA-
matched UCB with an adequate cell dose (≥ 2.5 × 107 nucleated cells/kg) is a suitable 
alternative when an HLA-matched URD is not available or when the transplant is urgent 
(Eapen et al., 2008 as cited in Smith &Wagner, 2009). 
Analyzing a more genetically heterogeneous group of patients, Kumar et al. (2008) also 
showed superior outcomes in UCB recipients relative to those transplanted with other 
sources of HSC. Patients receiving UCB had the lowest TRM and highest 3-year LFS (61% 
vs. 27%, 13% and 14% in the matched related donor, matched unrelated donor (MURD) and 
mismatched unrelated donor (MMURD) groups, respectively). Taken together, these results 
at least advocate for continued investigations into the use of UCB as an alternative stem cell 
source for the treatment of adults with hematological malignancy (Kumar et al., 2008 as 
cited in Smith & Wagner, 2009). 
In summary, these retrospective studies suggest for children, the first line HSC source 
would be a 6/6 MUCB provided that the cell dose is adequate. The probability of finding a 
6/6 MUCB, however, is low (~10%). However, results in recipients of 8/8 MUBM and 5/6 
MMUCB and 4/6 MMUCB are similar, suggesting that any of these options are reasonable. 
In this case, the decision must be individualized and based on the urgency of the transplant 
and potential need for future donor lymphocyte infusion (DLI). However, it is clear that 
with UCB, TRM increases with each degree of HLA-mismatch, so higher cell doses are 
needed with more HLA disparity. In addition, PBSC or BM is often a more realistic HSC 
option in adults due to cell dose limitations. Therefore, in adults, cell dose limitations with 
UCB units give the advantage to HLA matched BM and PBSC. For all patients, if an 8/8 
MUBM is not available, no one source stands out. UCB has the advantage of rapid 
availability while BM and PBSC have the advantage of availability of DLI (Smith & Wagner, 
2009). 
7.7 Liver diseases 
Liver cell transplantation is a promising technique for the treatment of metabolic liver 
disease, liver fibrosis and other end stage liver diseases. In vivo investigations showed that 
in carbon tetrachloride (CCl4)-induced cirrhosis in a rat model, hUCB-MSCs infusion 
demonstrated inhibition of TGF-ǃ, collagen type I and ǂ-smooth –muscle-actin (ǂ-SMA) 
expression as well as expression of hepatocyte-specific markers human ALB and AFP in 
injured liver (Jung et al., 2009), which indicated they might become an alternative source for 
liver-directed cell therapies (Campard et al., 2008). Several weeks after transplantation into 
the lesion livers of CCl4-induced liver fibrosis rats, significant reduction in liver fibrosis 
with lower levels of serum glutamic oxaloacetic transaminase, glutamic pyruvate 
transaminase, ǂ-SMA and TGF-ǃ in the liver was observed. Moreover, up-regulated 
expression of hepatic mesenchymal epithelial transition factor-phosphorylated type (Met-P) 
and hepatocyte growth factor was also found (Tsai et al., 2009 as cited in Fan et al., 2011). 
The engrafted hUCB-MSCs did not differentiate into hepatocytes expressing human ALB or 
AFP but secrete a variety of bioactive cytokines, including human cutaneous T cell-
attracting chemokine, leukemia inhibitory factor, and prolactin, which may benefit the 
restoration of liver function and promotion of regeneration (Tsai et al., 2009 as cited in Fan 
et al., 2011). Similar data were noted by Yan et al. (2009). In similar CCl-4 –injured mouse 
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hepatic injury, hUCB-MSCs were discovered to express tryptophan 2, 3-dioxygenase, 
human AFP, CK18, ǂ-SMA after administration into the damaged livers. Transplanted 
hUCB-MSCs could reduce hepatocyte denaturation, inhibit hepatocyte apoptosis, diminish 
serum aminotransferases and facilitate hepatocyte proliferation (Yan et al., 2009 as cited in 
Fan et al., 2011).       
Lin et al. (2010)  tested  the use of WJ stem cells (WJSCs) in treating chemically induced liver 
fibrosis via intraperitoneal injection of thioacetamide. They noticed that transplanted cells 
were distributed in the fibrotic area and around blood vessels, and hepatic recovery was 
accelerated. Serum prothrombin time significantly recovered, and serum albumin also 
improved at 21 days posttransplantation whereas collagen accumulation also decreased at 
14 days. Thus, human WJSCs promoted recovery after chronic liver damage. Moreover, 
transplanted WJSCs produced albumin, hepatocyte growth factor (HGF), and 
metalloproteinase (MMP) after transplantation to chemically injured liver, indicating that 
WJSC may help to decrease liver collagen and thus may be useful for treating liver fibrosis 
(Lin et al.,  2010).  According to all these results, hUCB-MSCs could be useful in liver 
therapy. It should not be forgotten that liver contains endogenous abundant progenitor cells 
for recovery of liver damage. Therefore, it is currently difficult to determine which stem 
/progenitor cell populations are best for liver disease therapy (Kim et al., 2010).  
7.8 Lung diseases  
Progression of acute respiratory distress syndrome is documented by loss of lung tissue as a 
result of inflammation and fibrosis. The role of term human UC cells derived from WJ with 
a phenotype consistent with MSCs was tested in the treatment of a bleomycin-induced 
mouse model of lung injury. Injected MSCs were located in the lung 2 weeks later only in 
areas of inflammation and fibrosis but not in healthy lung tissue. The administration of 
MSCs decreased inflammation, inhibited the expression of TGF-beta, IFN-gamma, and the 
proinflammatory cytokines macrophage migratory inhibitory factor and TNF-ǂ and reduced 
collagen concentration in the lung. MSCs also increased matrix metalloproteinase-2 levels 
and reduced their endogenous inhibitors, tissue inhibitors of matrix metalloproteinases, 
favoring a pro-degradative milieu following collagen deposition. Notably, injected human 
lung fibroblasts did not influence either collagen or matrix metalloproteinase levels in the 
lung. The results of this study suggest that MSCs participate in anti-fibrosis in lung injury 
and may increase lung repair if used to treat acute respiratory distress syndrome (Moodley 
et al., 2009). Others examined whether intratracheal or intraperitoneal transplantation of 
human UCB-derived MSCs can attenuate hyperoxia-induced lung injury in 
immunocompetent newborn rats. Wild-type rats were randomly exposed to 95% oxygen or 
air from birth and in the transplantation groups, a single dose of PKH26-labeled human 
UCB-derived MSCs was administered either intratracheally (2 x 106 cells) or 
intraperitoneally (5 x 105) cells) at postnatal day 5. The harvested lungs were examined after 
10 days and two abilities of hUCB-MSCs, immune modulation and differentiation potential 
towards the respiratory epithelium were assessed. Despite one fourth dosage of MSCs, 
significantly more PKH26-labeled donor cells were recovered with intratracheal 
administration than with intraperitoneal administration both during normoxia and 
hyperoxia. The hyperoxia-induced impaired alveolarization and increased level of TNF-
alpha and TGF-beta mRNA, alpha-SMA protein, and collagen were significantly alleviated 
only with intratracheal MSCs transplantation whereas the hyperoxia-induced increase in the 
number of TUNEL-positive cells, myeloperoixdase activity, and the level of IL-6 mRNA 
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were significantly attenuated with both intratracheal and intraperitoneal MSCs 
transplantation. As MSCs differentiated into respiratory epithelium in vitro and a few 
PKH26-positive donor cells were colocalized with pro surfactant protein C in the damaged 
lungs, hUCB-MSCs could be employed in cell therapy via both anti-inflammation and 
regeneration in hypoxia induced lung injury, representing a possible candidate for the new 
therapeutic modality for the hyperoxia-induced neonatal lung diseases, such as clinical 
bronchopulmonary dysplasia (Chang et al., 2009; Malgieri et al., 2010).  
7.9 Cartilage regeneration 
Mature articular cartilage is vulnerable to injuries and disease processes that cause 
irreversible tissue damage because of its limited capacity for self-repair. UCB is a source of 
MSCs which can give rise to cells of different lineages, including cartilage or bone (Mara et 
al., 2010). In fact hUCB-MSCs have much higher chondrogenic differentiation potentials 
which might lead to regeneration of damaged cartilage. In addition to this chondrogenic 
differentiation potential of MSCs, recent advances in our understanding of the regeneration 
mechanism for cartilage defects have demonstrated that MSCs also show potent 
immunosuppression and anti-inflammatory effects ( Di Nicola et al., 2002; Hao et al., 2009, 
Oh et al., 2008, Wang et al., 2009 as cited in Kim et al., 2010). These properties might be due 
in part to some specific secreted cytokines and growth factors, suggesting that chondrogenic 
differentiation and paracrine actions might be involved in replacement of damaged cartilage 
tissues and stimulation of the regeneration process (Kim et al., 2010). Wang et al. (2009) 
conducted for the first time a 6-week study comparing the differentiation potential of 
hBMSCs and hUCMSCs towards condrocytes in a three-dimensional (3D) scaffold. They 
concluded that hUCMSCs may be a desirable option for use as a mesenchymal cell source 
for fibrocartilage tissue engineering, based on abundant type I collagen and aggrecan 
production of hUCMSCs in a 3D matrix. Anyway, the authors stated that further 
investigation are warranted in order to find the signals that best promote also type II 
collagen production of hUCMSCs for hyaline cartilage engineering (Wang et al., 2009). 
Similar, a very recent study demonstrated that functionally, CB-MSC could be more readily 
induced to differentiate into chondrocytes than could BM-MSC and adipose tissue-MSC 
(AT-MSC). Moreover, CB-MSC showed immunosuppressive activity equal to that of BM-
MSC and AT-MSC, indicating CB a practical source of MSC for cell therapy and 
regenerative medicine through the use of the well established CB banking system (Zhang et 
al., 2011). Another attempt to differentiate cells from UCB into chondrocytes with insulin-
like growth factor 1 (IGF-1) and transforming growth factor-ss3 (TGF-ss3) showed that TGF-
ss3 used in micromass culture is the best growth factor for promoting the proliferation and 
differentiation of mesenchymal cells from UCB during chondrogenesis. The western blot 
analysis revealed that after 3 weeks, the expression of type II collagen was greater in 
micromass culture with TGF-ss3 (Mara et al., 2010).  
Two representative common diseases of cartilage degeneration include osteoarthritis and 
rheumatoid arthritis. Rheumatoid arthritis (RA) is a T-cell-mediated systemic autoimmune 
disease that primarily attacks synovial joints, leading to articular destruction and functional 
disability. The study by Liu et al. (2010) is the first report of the UC-MSCs use in the 
treatment of RA. The potential immunosuppressive effects of human UC-MSCs in RA were 
evaluated, too. Both the actions of UC-MSCs on the responses of fibroblast-like synoviocytes 
(FLSs) and T cells in RA patients and the possible molecular mechanism mediating this 
immunosuppressive effect of UC-MSCs and the therapeutic effects of systemic infusion of 
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human UC-MSCs on collagen-induced arthritis (CIA) in a mouse model were explored. 
They demonstrated that UC-MSCs exerted a profound inhibitory effect on the proliferation, 
invasive behavior and inflammatory responses of FLSs, suppressed T cell activation in vitro 
and induced the generation of regular T cells (Tregs). More importantly, in mice, systemic 
infusion of UC-MSCs significantly reduced the severity of CIA, strongly suggesting that UC-
MSCs might be a therapeutic strategy in RA. In addition, the immunosuppressive activitiy 
of UC-MSCs could be prolonged by the participation of Tregs (Liu et al., 2010). Despite 
growing evidence, the molecular mechanisms underlying cartilage repair and regeneration 
by hUCB-MSCs remain not settled. Therefore, extensive studies of hUCB-MSCs therapeutic 
mechanisms are required for an understanding of their regenerative potential and for 
efficient and safe clinical application. Supported by the clinical trial phase I/II results 
(NCT01041001), adult stem cell therapy using hUCB-MSCs for cartilage degenerative 
disease might be a promising alternative to previous treatments (Kim et al., 2010).       
 7.10 Gene therapy 
Retroviral mediated gene transfer has been shown to be an efficient method for introducing 
genetic sequences into mammalian cells (Bernstein et al., 1985; Friedmann et al., 1989 as 
cited in Lu et al., 1996) and gene replacement therapy has been proposed for many single 
gene disorders (Lu et al., 1996). Adeno-associated viruses (AAV) can also be used as a 
vehicle for gene transfer. MSCs are amenable to be genetically modified, which makes them 
become a promising platform for cell and gene therapy and broadens their potential 
therapeutic applications in several fields, including improvement engraftment following 
stem cell transplantation and acceleration of hematopoietic reconstitution, treatment of 
severe graft-versus-host disease, utilization in targeting tumors and delivering anti-cancer 
molecules as well as cellular vehicle for protein-supplement gene therapy (Fritz & 
Jorgensen, 2008; Kumar et al., 2008 as cited in Fan et al., 2011). The strategy that uses 
therapeutic gene-transfected hUCMSCs as cellular vehicles for targeted biologic agent 
delivery has solved the problem of short half-life or excessive toxicity of biological agent(s) 
in vivo. Administration of hUC-MSCs expressing interferon-ǃ with (Rachakatla et al., 2008 
as cited in Fan et al., 2011) or without 5-fluorouracil (Rachakatla et al., 2007 as cited in Fan et 
al., 2011) was found to target to experimentally developed lung tumors and significantly 
reduce the tumor burden. Furthermore, the co-culture  of a small numbe of IFN-beta gene-
transfected hUCMSCs (IFN-beta-hUCMSCs) with the human bronchioloalveolar carcinoma 
cell lines H358 or SW1573 significantly inhibited growth of both types of carcinoma cell 
lines, whereas systemic administration of IFN-beta-hUCMSCs markedly attenuated growth 
of orthotopic H358 bronchioloalveolar carcinoma xenografts in SCID mice by increasing 
apoptosis. These results clearly indicate that IFN-beta-hUCMSCs caused cell death of 
bronchioloalveolar carcinoma cells through IFN-beta production, thereby attenuating tumor 
growth in vivo, suggesting that IFN-beta-hUCMSCs are a powerful anti-cancer 
cytotherapeutic tool for bronchioloalveolar carcinoma (Matsuzuka et al., 2010). HUC-MSCs 
modified to express BDNF were also found to improve neurological function and increase 
NSE-positive cells while decrease GFAP-positive cells and number of apoptosis cells after 
being delivered into the edge of lesion in athymic mice brain injury model (Zhang et al., 
2009 as cited in Fan et al., 2011). In addition hUC-MSCs can be genetically modified to 
express biologically active human factor IX and serve as an efficient drug delivery vehicle 
for somatic gene therapy of hemophilia B (Chen et al., 2009 as cited in Fan et al., 2011). hUC-
MSCs might have a migratory capacity toward glioma cells and therefore can also serve as a 
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vector for gene therapy against brain tumors. Soluble factors including chemokines or 
growth factors expressed and released by glioma cells mediate the tropism of MSCs for 
gliomas. In the study by Park et al. (2011) the overexpression of the stromal cell-derived 
factor-1ǂ (SDF-1ǂ) receptor, chemokine receptor 4 (CXCR4), on hUCB-MSCs resulted in 
enhanced migratory capacity of MSCs toward gliomas. Furthermore, CXCR4 transfected 
hUCB-MSCs (hMSCs-CXCR4) showed a stronger migration capacity toward glioma cells in 
vitro compared with control MSCs, and also exhibited enhanced migration to glioma cells in 
an intracranial human malignant glioma xenograft model. These results indicate that SDF-
1ǂ/CXCR4 could be involved in recruitment of hUCB-MSCs to glioma cells and that 
overexpression of CXCR4 may be a useful tool for stem cell-based glioma therapy (Park et 
al., 2011). It has also been suggested that the genetic alteration of stem cells can function as a 
mechanism which could deliver specific gene products to parts of tissue ischemia to boost 
the repair process (Byun et al., 2001; Melo et al., 2004; Yi et al., 2006 as cited in Goldberg et 
al., 2007) and it was shown to be associated with restored physiological functions after AMI 
(Chen et al., 2005 as cited in Arien-Zakay et al., 2010). In preclinical studies, UCB CD34+ 
transfected with VEGF or Ang-1 have been shown to enhance the process of tissue repair in 
a murine LAD ligation model (Goldberg et al., 2007) and UCB MNCs modified to express 
VEGF have demonstrated their efficiency in a hindlimb model of chronic ischemia (Ikeda et 
al., 2004 as cited in Goldberg et al., 2007).  Additionally, autologous CB CD 34+ transduced 
with human adenosine deaminase (ADA) gene were infused in children with ADA 
deficiency (Kohn et al., 1995 as cited in Lu et al., 1996).     
8. Cord blood stem cells transplantation: Advantages and disadvantages 
The UCB as a source of human stem cells has proved to be highly advantageous as 
compared to peripheral blood and bone marrow. UCB has more hematopoietic stem cells 
per volume than PB and BM (Rogers & Casper, 2004) and the immature hematopoietic stem 
cells and progenitor cells from cord blood seem to be of good quality (Lu et al., 1996). Stem 
cells remain in the placenta and umbilical cord after delivery and an average of 120 ml of 
blood can be collected without risking the health of either the mother or the baby (Rogers & 
Casper, 2004). Cord blood harvesting is thus simple, easy, painless and non-invasive for the 
donor, contrary to BM aspiration and consequently there are more potential donors than for 
BM (Malgieri et al., 2010). Moreover, the procedure does not involve ethical and technical 
issues (Wu et al., 2009 as cited in Malgieri et al., 2010). Different from BM transplants which 
require general anaesthesia and surgical transfer of the donor marrow to the recipient, UCB 
stem cell transplantation is a simple intravenous infusion of the hematopoietic stem cells, 
which find their way to the BM for engraftment (Rogers & Casper, 2004). Moreover, due to 
the fact that cord blood units are priory stored in public and private UCB banks (Malgieri et 
al., 2010) they are quickly available, an advantage which is crucial to high-risk patients with 
unstable disease (Barker et al., 2002 as cited in Barker & Wagner, 2003), whereas BM has to 
be collected from the donor just before transplantation and there is always the risk of last 
minute consent refusal (Malgieri et al., 2010). Successful transplantation require allogeneic 
grafts matching most, if not all, of the six to ten major HLA antigens between host and 
donor (Malgieri et al., 2010). The majority of the CB transplantations have been performed to 
treat patients with malignant and non-malignant diseases (Ballen et al., 2001 as cited in 
Rogers & Casper, 2004) and many of these originated from sibling donors with partial or 
complete HLA matching. The incidence of acute GVHD has been lower than the expected 
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rate in a pediatric population who received transplants with BM. Interestingly, acute GVHD 
has not been related to the degree of HLA matching, thus proving that the use of cord blood 
itself is responsible for the lowered risk (Gluckman et al., 2001; Yu et al., 2001 as cited in 
Rogers & Casper, 2004). Consequently, the HLA type does not have to be a perfect match for 
allogeneic cord blood transplantation because the possibility that these cells induce 
immunological reactions is lower than in the case of BM cells (Malgieri et al., 2010). For a 
given HLA match, the risk of GVHD is lower with UCBT than with BMT, thus allowing 
UCBT with 1-2 antigen HLA-mismatched (Barker & Wagner, 2003). The UCB reduced graft-
versus-host reactivity when compared with adult-derived marrow grafts can be explained 
through the relative immune immaturity of the newborn cells (MSCs and hematopoietic 
stem cells) (Malgieri et al., 2010). In this way, the donor poll could be extended and patients 
belonging to ethnic minorities could be better represented on BM donor registries. 
Moreover, UCB does not imply risk for the donor or donor attrition and has the advantage 
of lower cytomegalovirus (CMV) transmission.   
The major disadvantage of UCB is the limited cell dose, which is of particular relevance to 
the application of UCB transplants to adults (Rogers & Casper, 2004). Moreover, while 
processing, testing and freezing the collected CB in a cord blood bank, there is usually a 10-
20% loss from the initial blood volume and cell dose (Stanevsky et al., 2009). Moreover, there 
is an increased risk of contamination with any cell culture manipulation (Malgieri et al., 
2010) and it appears that MSCs from UCB have lower success rate of isolation if compared 
with MSCs from BM (63% vs 100% ) (Kern et al., 2006 as cited in Malgieri et al., 2010). The 
less experience, the present insufficient standardization of each steps between different 
banks, as well as inadequate storage policy, may lead to an even greater cell loss. Given that 
some of the CB transplants are performed with cell dose near the engraftment threshold, 
modest loss of potency of a product may have a major impact on clinical outcome. Indeed, 
delayed engraftment due to low cell dose represents one of the main disadvantages and the 
main restriction of cord blood transplants (Stanevski et al., 2009). However, several 
strategies- such as improved collection techniques and more efficient cell processing and 
cryopreservation methods are developing in order to overcome these obstacles and obtain 
successful engraftment of adults as well as children. Other limitations include the potential 
risk of genetic disease transmission and lack of donor recall for collection of stem cells or 
donor lymphocytes in the URD setting (Barker & Wagner, 2003).  
9. Cord blood banking 
Currently, there is a huge interest in establishing and developing cord blood banks. 
Worldwide, more than 400,000 cord blood grafts are available in more than 50 cord blood 
banks. The cord blood collections are managed by cord blood bank networks named 
Netcord (www.netcord.org), international registries for outcome data collection named 
Eurocord (www.eurocord.org) and CIBMTR www.cibmtr.org. Eurocord is an international 
registry developed by the European Blood and Marrow Transplant group (EBMT), which 
includes more than 190 transplant centers in 36 countries all performing cord blood 
transplants. Eurocord is collaborating with EBMT and Netcord banks to gather clinical 
information and monitor all patients transplanted in or outside Europe with Netcord units. 
The Netcord group was established in 1998 to provide good practice in umbilical cord blood 
storage, facilitate donor search, improve the quality of the grafts, standardize excellence 
criteria on an international scale and importantly, to establish procedures for bank 
www.intechopen.com
  
Stem Cells in Clinic and Research 
 
50
accreditation in collaboration with FACT (Foundation on Accreditation in Cell Therapy). All 
the practical aspects of cord blood banking, such as mother informed consent, collection 
techniques, labelling and identification, infectious disease and genetic disease testing, HLA 
typing, methodology of cell processing, cryopreservation, transportation and release have 
been extensively published. All these aspects are detailed in the last version of the Netcord-
FACT Standards (www.factwebsite.org). 
Currently, there are increasing numbers of international exchanges of cord blood units. 
Profit entities such as private banks, store directed donations collected by obstetricians from 
babies born into families who intend to use the cord blood for the baby from whom it came 
(autologous donation) or for another family member in need of future transplantation 
therapy. 
10. Future perspectives 
The differentiation potential of UCMSC makes them the perfect candidate for a wide range 
of clinical applications. UC-derived MSCs showed to be multipotent and their 
differentiation abilities does not seem to be restricted to the mesodermal lineages, since the 
cells could be successfully induced to neurones, pancreatic and liver cells. Latest evidences 
suggest, that UC-MSC populations contain a subset of primitive cells. Therefore, the 
identification and characterization of these sub-populations in the future is of decisive 
importance. Another issue of great clinical importance is the question of whether the 
differentiation potential of the isolated populations is dependent on their location in the UC-
tissue. Recently, MSCs markers were developed and may be helpful in this matter. 
Additionally, first in vitro and in vivo animal studies showed immune-privileged and 
immune-modulatory properties of UC-derived MSCs. Due to immune-modulatory 
properties low levels of rejection were observed in all reports of in vitro transplantation 
experiments and good results in tissue engraftments were noted. Therefore further studies 
and clinical trials will clarify whether the in vivo properties of UC-derived MSCs after 
transplantation exhibits same effects. 
One of the ambitious aims of regenerative medicine is the engineering of tissue in vitro. Few 
but very promising applications of UC-derived MSCs have been reported in this field. 
Biopolymer scaffolds, mechanical strain approaches, or 3D bioreactors for tissue generation, 
which were successfully applied with MSCs from other sources will be of great clinical 
interest in the future. 
In the effort to overcome incurable diseases, it may only be a question of time until UC-
derived MSCs will be successfully used for clinical and tissue engineering applications. 
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